A WHIM satisfactorily addressed.
In this issue of Blood, McDermott et al present the intriguing, clinically relevant, and perhaps unexpected findings for the efficacy and safety of long-term administration of low-dose plerixafor treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.